Our findings suggest that inhibition of the enzymatic activity of USP52 or disruption of the association of USP52 with ASF1A, combined with chemo- or radio-therapy, could potentially improve the treatment of breast cancer. The gene discussed is ASF1A; the disease is breast cancer.